Manufacturers/E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
82 drugs in NADAC|82 Generic,0 Brand
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. lists 82 NDCs in the CMS NADAC file (82 generic, 0 brand), at an average NADAC of $0.59 per unit, with a week-over-week move of +0.6% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
82
82G / 0B
Avg Price / Unit
$0.5882
$0.03 – $4.73
Avg 7d Change
+0.63%
Across 58 drugs with changes
7d Activity
37↑21↓24 flat
of 82 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
How many drugs does E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. make?
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. lists 82 NDCs in the CMS NADAC file — 82 generic and 0 brand products.
What is the average price of E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. drugs?
The average NADAC across E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.'s portfolio is $0.5882 per unit, ranging from $0.0253 to $4.7346.
What types of drugs does E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. make?
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. makes drugs across 7 FDA pharmacologic classes. The most common by NDC count are Corticosteroid (56), Azole Antifungal (11), Lincosamide Antibacterial (6), Calcineurin Inhibitor Immunosuppressant (6), Amide Local Anesthetic (4).
Has E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. had any drug recalls?
No FDA enforcement recalls are matched to E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. in the openFDA feed.
How has E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.'s pricing changed recently?
Over the past 7 days, 37 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. products rose and 21 fell, with a portfolio-wide average change of +0.6%.